Crucell is a fully-integrated biopharmaceutical company. We focus on developing, producing and marketing products that combat infectious diseases. We are the largest independent vaccine company in the world.

Headquartered in Leiden, The Netherlands, Crucell currently employs about 1100 people and has subsidiaries in Switzerland, Spain, Sweden, Italy, Korea and the United States. Crucell N.V. is listed on Euronext and NASDAQ (CRXL) and the SWX Swiss Exchange (CRX). At Crucell, we’re bringing innovation to global health.

As the sixth largest vaccine company worldwide, Crucell presents a strong portfolio of products: 

Paediatric:

• Quinvaxem^® - Fully liquid vaccine for protection against five childhood diseases
• Hepavax-Gene^® - Recombinant hepatitis B vaccine
• MoRu-Viraten^® - Vaccine for protection against measles and rubella (all age groups)
• Epaxal® Junior - Low dosage unique aluminum-free hepatitis A vaccine (0.25ml)

Travel and endemic:

• Epaxal^® - Unique aluminum-free hepatitis A vaccine
• Vivotif^® - Unique oral typhoid vaccine
• Dukoral^® - Internationally licensed oral vaccine with documented efficacy against diarrhea caused by cholera

Respiratory:

• Inflexal^® V – Virosomal adjuvanted influenza (all age groups)

Crucell has a broad development pipeline, including vaccines and proteins. Several Crucell products are based on our unique PER.C6^® production technology. Crucell licenses this and other cutting edge technologies to the biopharmaceutical industry. Important partners and licensees are DSM Biologics, sanofi aventis, GSK, Merck & Co. and the US National Institutes of Health (NIH).

Valuable Products 

Innovative Technology

Solid Financial Position

Strong Management